CDK14 (Cyclin-Dependent Kinase 14) is a serine/threonine kinase belonging to the CDK family, which plays critical roles in regulating cell cycle progression, transcription, and neuronal development. Unlike canonical CDKs (e.g., CDK1/2/4/6), CDK14 activity is tightly linked to its binding partner, cyclin Y, and it is implicated in the Wnt/β-catenin signaling pathway. Studies suggest CDK14-cyclin Y complexes phosphorylate components of the Wnt pathway, influencing cell proliferation, differentiation, and tissue homeostasis. Dysregulation of CDK14 has been associated with cancers (e.g., colorectal, pancreatic), neurological disorders, and developmental defects, highlighting its potential as a therapeutic target.
CDK14 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific antibodies help identify CDK14 overexpression in tumors, correlate it with disease progression, or explore its role in neurodevelopment. Challenges include ensuring antibody specificity due to high homology among CDK family members. Recent research also investigates CDK14's interaction networks and post-translational modifications, aided by reliable antibodies. Developing selective CDK14 inhibitors remains an active area, with antibodies supporting target validation and mechanistic studies in preclinical models.